Skip to main content
. Author manuscript; available in PMC: 2018 Jan 23.
Published in final edited form as: Clin Cancer Res. 2009 Sep 1;15(17):5323–5337. doi: 10.1158/1078-0432.CCR-09-0737

TABLE 3.

Cancer antigen pilot prioritization: ranking based on predefined & preweighted criteria

CRITERIA► CUMMU-
LATIVE
SCORE		 THERAPEUTIC
FUNCTION
(0.32)		 IMMUNO-
GENICITY
(0.17)		 ONCO-
GENICITY
(0.15)		 SPECIFICITY
(0.15)		 EXPRES-
SION LEVEL
& %
POSITIVE
CELLS
(0.07)		 STEM CELL
EXPRES-
SION
(0.05)		 NUMBER
OF
PATIENTS
WITH
ANTIGEN
POSITIVE
CANCERS
(0.04)		 NUMBER
OF
EPITOPES
(0.04)		 CELLULAR
LOCATION
OF EXPRES-
SION
(0.02)
ANTIGENS
▼
(Rank/
Reference
number &
Name)
1. WT1 0.81 0.75
Fair data		 1.0
Imm in trials		 1.0
Oncogenic		 0.54
Oncofetal		 0.37
High most		 1.0
Stem cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
2. MUC1 0.79 0.75
Fair data		 1.0
Imm in trials		 1.0
Oncogenic		 0.23
Post-
translational
changes		 1.0
High all		 1.0
Stem cells		 1.0
Many patients
high level		 1.0
Multiple		 0.25
Surface
Circulating
3. LMP2 0.78 0.75
Fair data		 1.0
Imm in trials		 0.34
Persistent viral		 1.0
Absolute		 0.37
High most		 1.0
Stem cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
4. HPV E6 E7 0.77 0.89
Very Strong-8
Adequate-6
Fair-1		 1.0
Imm in trials		 0.34
Persistent viral		 1.0
Absolute		 0.23
Low all		 0.73
All stages-11
Stem cells-3		 0.16
Many patients
lower level		 1.0
Multiple		 0.95
Internal MHC
5. EGFRvIII 0.76 0.76
Fair-12
Adequate-2		 1.0
Imm in trials		 0.62
Oncogenic-8
Uncertain but
decreased
survival-7		 1.0
Absolute		 0.37
High most		 1.0
Stem cells		 0.11
High level -
Small subset		 0.13
Single		 1
Surface Little
Circulation
MHC
6. HER-2/neu 0.75 0.85
Adequate		 1.0
Imm in trials		 1.0
Oncogenic		 0.35
Over
expressed		 0.37
High most		 0.66
All stages		 0.11
High level -
Small subset		 1.0
Multiple		 0.25
Surface
Circulating
7. Idiotype 0.75 0.76
Fair-13
Adequate-2		 1.0
Imm in trials		 0.12
Differentiation		 1.0
Absolute		 1.0
High all		 0.66
All stages		 0.14 Unique 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
8. MAGE A3 0.71 0.79
Fair-9
Adequate-6		 1.0
Imm in trials		 0.25
Uncertain but
decreased
survival		 0.54
Oncofetal		 0.37
High most		 1.0
Stem cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
9. p53 non-
mutant		 0.67 0.42
Fair-9
N/A-7		 1.0
Imm in trials		 1.0
Oncogenic		 0.35
Over
expressed		 0.37
High most		 1.0
Stem cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
10. NY-ESO-1 0.66 0.75
Fair data		 1.0
Imm in trials		 0.25
Uncertain but
decreased
survival		 0.54
Oncofetal		 0.37
High most		 1.0
Stem cells		 0.11.0
High level -
Small subset		 1.0
Multiple		 0.95
Internal MHC
11. PSMA 0.65 0.75
Fair data		 1.0
Imm in trials		 0.25
Uncertain but
decreased
survival		 0.21
Tissue
specific		 1.0
High all		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
12. GD2 0.65 0.75
Fair data		 1.0
Imm in trials		 0.12
Differentiation		 0.35
Over
expressed		 1.0
High all		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.62
Surface with
indeterminate
circulating
13. CEA 0.62 0.75
Fair data		 1.0
Imm in trials		 0.12
Differentiation		 0.35
Over
expressed		 0.37
High most		 0.66
All stages		 1.0
Many patients
high level		 1.0
Multiple		 0.25
Surface
Circulating
14.
MelanA/MART1		 0.60 0.77
Fair-11
Superb-1.0
Adequate-1
T cell Tx-1		 1.0
Imm in trials		 0.12
Differentiation		 0.21
Tissue
specific		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
15. Ras-mutant 0.60 0.1
Animal		 1.0
Imm in trials		 1.0
Oncogenic		 1.0
Absolute		 0.23
Low all		 1.0
Stem cells		 0.16
Many patients
lower level		 0.13
Single		 0.95
Internal MHC
16. gp100 0.59 0.75
Fair data		 1.0
Imm in trials		 0.12
Differentiation		 0.21
Tissue
specific		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
17. p53 mutant 0.58 0.35
N/A-8
Fair-7		 1.0
Imm in trials		 1.0
Oncogenic		 0.1
Unique
random
mutations		 1.0
High all		 0.77 All
stages-10
Stem cells-5		 0.14 Unique 0.13
Single		 0.95
Internal MHC
18. Proteinase3
(PR1)		 0.57 0.7
Fair-15
N/A-1		 1.0
Imm in trials		 0.12
Differentiation		 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 0.13
Single		 0.95
Internal MHC
19. Bcr-abl 0.56 0.00 1.0
Imm in trials		 1.0
Oncogenic		 1.0
Absolute		 0.23
Low all		 1.0
Stem cells		 0.16
Many patients
lower level		 0.13
Single		 0.95
Internal MHC
20. Tyrosinase 0.56 0.65
T cell Tx		 1.0
Imm in trials		 0.12
Differentiation		 0.21
Tissue
specific		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
21. Survivin 0.55 0.1
Animal		 1.0
Imm in trials		 1.0
Oncogenic		 0.35
Over
expressed		 0.37
High most		 0.66
All stages		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
22. PSA 0.55 0.75
Fair data		 1.0
Imm in trials		 0.12
Differentiation		 0.21
Tissue
specific		 0.08
Low most		 0.66
All stages		 0.16
Many patients
lower level		 1.0
Multiple		 0.25
Surface
Circulating
23. hTERT 0.54 0.15
Preexistent		 1.0
Imm in trials		 1.0
Oncogenic		 0.35
Over
expressed		 0.23
Low all		 1.0
Stem cells		 0.16
Many patients
lower level		 1.0
Multiple		 0.95
Internal MHC
24. Sarcoma
translocation
breakpoints		 0.54 0.00 0.39
T cell
observed		 1.0
Oncogenic		 1.0
Absolute		 1.0
High all		 1.0
Stem cells		 1.0
Many patients
high level		 0.13
Single		 0.95
Internal MHC
25. EphA2 0.53 0.1
Animal		 1.0
Imm in trials		 1.0
Oncogenic		 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation MHC
26. PAP 0.52 0.69
Fair-9
Adequate-4
Animal-2		 1.0
Imm in trials		 0.12
Differentiation		 0.21
Tissue
specific		 0.23
Low all		 0.2
Most cancer
cells		 0.16
Many patients
lower level		 1.0
Multiple		 0.25
Surface
Circulating
27. ML-IAP 0.50 0.00 1.0
Imm in trials		 1.0
Oncogenic		 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
28. AFP 0.49 0.15
Preexistent		 1.0
Imm in trials		 0.24
Uncertain but
decreased
survival-11
Differenetiation-1		 0.54
Oncofetal		 0.37
High most		 1.0
Stem cells		 1.0
Many patients
high level		 1.0
Multiple		 0.25
Surface
Circulating
29. EpCAM 0.48 0.1
Animal		 1.0
Imm in trials		 0.12
Differentiation		 0.35
Over
expressed		 1.0
High all		 1.0
Stem cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
30. ERG
(TMPRSS2
ETS fusion
gene)		 0.48 0.00 0.39
T cell
observed		 1.0
Oncogenic		 1.0
Absolute		 0.37
High most		 0.66
All stages		 1.0
Many patients
high level		 0.13
Single		 0.95
Internal MHC
31. NA17 0.48 0.59
Fair-11
N/A-3		 1.0
Imm in trials		 0.00 0.35
Over
expressed		 0.00 0.00 1.0
Many patients
high level		 0.13
Single		 0.95
Internal MHC
32. PAX3 0.47 0.00 1.0
Imm in trials		 1.0
Oncogenic		 0.54
Oncofetal		 0.08
Low most		 0.2
Most cancer
cells		 0.00 1.0
Multiple		 0.95
Internal MHC
33. ALK 0.46 0.00 0.39
T cell
observed		 1.0
Oncogenic		 0.42
Overexressed
-6 Absolute-3
N/A-3		 1.0
High all		 1.0
Stem cells		 1.0
Many patients
high level		 0.27
Single-8
Multiple-2		 0.95
Internal MHC
34. Androgen
receptor		 0.45 0.1
Animal		 0.39
T cell
observed		 1.0
Oncogenic		 0.35
Over
expressed		 0.37
High most		 0.66
All stages		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
35. Cyclin B1 0.44 0.1
Animal		 0.39
T cell
observed		 1.0
Oncogenic		 0.35
Over
expressed		 0.32
High most-7
Low all-4		 0.66
All stages		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
36. Polysialic
Acid		 0.44 0.00 1.0
Imm in trials		 0.12
Differentiation		 0.54
Oncofetal		 1.0
High all		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
37. MYCN 0.42 0.00 0.39
T cell
observed		 1.0
Oncogenic		 0.54
Oncofetal		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
38. RhoC 0.42 0.00 0.39
T cell
observed		 1.0
Oncogenic		 0.35
Over
expressed		 0.37
High most		 0.66
All stages		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
39. TRP-2 0.42 0.1
Animal		 1.0
Imm in trials		 0.12
Differentiation		 0.21
Tissue
specific		 0.37
High most		 1.0
Stem cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
40. GD3 0.41 0.00 1.0
Imm in trials		 0.12
Differentiation		 0.35
Over
expressed		 1.0
High all		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
41. Fucosyl
GM1		 0.41 0.00 1.0
Imm in trials		 0.12
Differentiation		 0.35
Over
expressed		 1.0
High all		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
42. Mesothelin 0.41 0.00 1.0
Imm in trials		 0.25
Uncertain but
decreased
survival		 0.35
Over
expressed		 0.37
High most		 0.66
All stages		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
43. PSCA 0.41 0.75
Fair data		 0.11
Animal		 0.12
Differentiation		 0.21
Tissue
specific		 0.37
High most		 0.2
Most cancer
cells		 0.16
Many patients
lower level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
44. MAGE A1 0.40 0.00 1.0
Imm in trials		 0.25
Uncertain but
decreased
survival		 0.54
Oncofetal		 0.00 1.0
Stem cells		 0.1.06
Many patients
lower level		 1.0
Multiple		 0.95
Internal MHC
45. sLe(a) 0.40 0.00 1.0
Imm in trials		 0.12
Differentiation		 0.35
Over
expressed		 1.0
High all		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.25
Surface
Circulating
46. CYP1B1 0.40 0.00 1.0
Imm in trials		 0.00 0.35
Over
expressed		 1.0
High all		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
47. PLAC1 0.39 0.00 0.39
T cell
observed		 1.0
Oncogenic		 0.54
Oncofetal		 0.37
High most		 0.2
Most cancer
cells		 0.11
High level -
Small subset		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
48. GM3 0.38 0.1
Animal		 1.0
Imm in trials		 0.12
Stroma		 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.25
Surface
Circulating
49. BORIS 0.38 0.1
Animal		 0.11
Animal		 0.1
Oncogenic		 0.54
Oncofetal		 0.08
Low most		 0.66
All stages		 0.16
Many patients
lower level		 1.0
Multiple		 0.95
Internal MHC
50. Tn 0.37 0.00 1.0
Imm in trials		 0.25
Uncertain but
decreased
survival		 0.23
Post-
translational
changes		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
51. GloboH 0.37 0.00 1.0
Imm in trials		 0.12
Differentiation		 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
52. ETV6-AML 0.37 0.00 0.00 1.0
Oncogenic		 1.0
Absolute		 0.23
Low all		 0.66
All stages		 0.11
High level -
Small subset		 0.13
Single		 0.95
Internal MHC
53. NY-BR-1 0.36 0.00 0.39
T cell
observed		 0.12
Differentiation		 1.0
Absolute		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
54. RGS5 0.35 0.00 1.0
Imm in trials		 0.00 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
55. SART3 0.35 0.00 1.0
Imm in trials		 0.00 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
56. STn 0.34 0.00 1.0
Imm in trials		 0.25
Uncertain but
decreased
survival		 0.23
Post-
translational
changes		 0.37
High most		 0.2
Most cancer
cells		 0.16
Many patients
lower level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
57. Carbonic
anhydrase IX		 0.34 0.00 1.0
Imm in trials		 0.00 0.35
Over expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.25
Surface
Circulating
58. PAX5 0.33 0.00 0.39
T cell
observed		 1.0
Oncogenic		 0.21
Tissue
specific		 0.23
Low all		 0.2
Most cancer
cells		 0.16
Many patients
lower level		 1.0
Multiple		 0.95
Internal MHC
59. OY-TES1 0.32 0.00 0.1
Ab observed		 1.0
Oncogenic		 0.54
Oncofetal		 0.08
Low most		 0.2
Most cancer
cells		 0.16
Many patients
lower level		 1.0
Multiple		 0.95
Internal MHC
60. Sperm
protein 17		 0.30 0.1
Animal		 0.11
Animal		 0.25
Uncertain but
decreased
survival		 0.54
Oncofetal		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
61. LCK 0.28 0.00 1.0
Imm in trials		 0.00 0.35
Over
expressed		 0.00 0.00 0.00 1.0
Multiple		 0.95
Internal MHC
62. HMWMAA 0.27 0.1
Animal		 0.11
Animal		 0.00 0.35
Over
expressed		 1.0
High all		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
63. AKAP-4 0.26 0.1
Animal		 0.11
Animal		 0.12
Differentiation		 0.54
Oncofetal		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.25
Surface
Circulating
64. SSX2 0.26 0.00 0.39
T cell
observed		 0.25
Uncertain but
decreased
survival		 0.54
Oncofetal		 0.08
Low most		 0.2
Most cancer
cells		 0.11
High level -
Small subset		 1.0
Multiple		 0.95
Internal MHC
65. XAGE 1 0.23 0.00 0.1
Ab observed		 0.00 0.54
Oncofetal		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
66. B7H3 0.22 0.00 0.00 0.25
Uncertain but
decreased
survival		 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
67. Legumain 0.19 0.1
Animal		 0.11
Animal		 0.00 0.35
Over
expressed		 0.37
High most		 0.2
Most cancer
cells		 0.00 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
68. Tie 2 0.18 0.1
Animal		 0.11
Animal		 0.00 0.23
Post-
translational
changes		 0.00 0.00 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
69. Page4 0.17 0.00 0.00 0.12
Differentiation		 0.21
Tissue
specific		 0.37
High most		 0.00 1.0
Many patients
high level		 1.0
Multiple		 0.95
Internal MHC
70. VEGFR2 0.16 0.1
Animal		 0.11
Animal		 0.12
Stroma		 0.1
Stromal		 0.00 0.00 1.0
Many patients
high level		 1.0
Multiple		 0.25
Surface
Circulating
71. MAD-CT-1 0.15 0.00 0.1
Ab observed		 0.00 0.54
Oncofetal		 0.00 0.00 0.00 1.0
Multiple		 0.95
Internal MHC
72. FAP 0.14 0.1
Animal		 0.00 0.00 0.1
Stromal		 0.00 0.00 1.0
Many patients
high level		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
73. PDGFR-
beta		 0.14 0.00 0.11
Animal		 0.12Stroma 0.1
Stromal		 0.00 0.66
All stages		 0.00 1.0
Multiple		 1.0
Surface Little
Circulation
MHC
74. MAD-CT-2 0.14 0.00 0.1
Ab observed		 0.00 0.54
Oncofetal		 0.00 0.00 0.16
Many patients
lower level		 1.0
Multiple		 0.00
75. Fos-related
antigen 1		 0.13 0.1
Animal		 0.11
Animal		 0.00 0.1
Stromal		 0.00 0.00 0.11
High level -
Small subset		 1.0
Multiple		 1.0
Surface Little
Circulation
MHC

Row 1: Criteria are listed in descending order of weighting. The (numbers) refer to relative weighting of each criterion. The cumulative (numbers) total 1.

Column 1: Antigens are listed in descending order of ranking. The numbers refer to the ranking as well as to a literature reference for each antigen.

Column 2: Cumulative scores are listed in descending order of ranking. The cumulative score for each antigen is the sum product of pre-determined weights for the 9 criteria. Cumulative score for each antigen is the sum product of the weight of each Criteria multiplied by the score of the Sub-criteria. Total Score = (Weight of Criteria 1)×(Score of Sub-Criteria for Criteria 1) + (Weight of Criteria 2)×(Score of Sub-Criteria for Criteria 2) + (Weight of Criteria 3)×(Score of Sub-Criteria for Criteria 3) + etc.

Columns 3–11 Numbers represent the weight of the top Sub-criteria appropriate for that antigen within the Criteria denoted in the column. The terms are abbreviations for the names for the Sub-criteria. The full names and weighted scores for each Sub-criterion are presented in column 3 of Table 1. If there are no numbers following the term, the panel members all agreed on the Sub-criteria. If there are numbers following the terms, the panel members disagreed on what should be the top Sub-category. The numbers designate the number of votes for each Sub-category.